{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-013692","form_type":"8-K","ticker":"ABBV","cik":"0001551152","company_name":"AbbVie Inc.","filed_at":"2024-02-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.574227+00:00","generated_at":"2026-06-06T04:17:48.324151+00:00","sec_items":["7.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"AbbVie completes $31.26/share ImmunoGen acquisition; reaffirms FY2024 EPS guidance with $0.42 dilution","bullets":["Acquired all outstanding ImmunoGen shares for $31.26 each; ImmunoGen ceases trading on NASDAQ.","Adds ELAHERE (FRα-positive ovarian cancer ADC) and pipeline assets including IMGN-151 and pivekimab sunirine.","Reaffirms full-year 2024 adjusted diluted EPS guidance of $11.05-$11.25, now including $0.42 dilution from ImmunoGen and pending Cerevel.","Updates Q1 2024 adjusted EPS guidance to $2.26-$2.30 from $2.30-$2.34 due to $0.04 dilutive impact from ImmunoGen.","Expects the acquisition to be accretive to diluted EPS beginning in 2027 and significantly accretive over long term."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-013692","json":"https://secwatch.observer/filing/0001104659-24-013692.json","markdown":"https://secwatch.observer/filing/0001104659-24-013692.md","text":"https://secwatch.observer/filing/0001104659-24-013692.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924013692/0001104659-24-013692-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1551152/000110465924013692/tm245657d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T04:17:48.324151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}